Management and Outcomes of Unilateral Group D Tumors in Retinoblastoma

Saima Amin,1 Mays AlJboor,1 Mario D Toro,2,3 Robert Rejdak,2 Katarzyna Nowomiejska,2 Rashed Nazzal,4 Mona Mohammad,1 Maysa Al-Hussaini,5 Jakub Khzouz,5 Sara Banat,1 Reem AlJabari,1 Imad Jaradat,6 Mustafa Mehyar,1 Iyad Sultan,7 Ibrahim AlNawaiseh,1 Yacoub A Yousef1 1Department of Surgery (Ophthalmolo...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Amin S, AlJboor M, Toro MD, Rejdak R, Nowomiejska K, Nazzal R, Mohammad M, Al-Hussaini M, Khzouz J, Banat S, AlJabari R, Jaradat I, Mehyar M, Sultan I, AlNawaiseh I, Yousef YA
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2021
Materias:
Acceso en línea:https://doaj.org/article/f4d4a9f90d534338968c32c981cb2d2e
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:f4d4a9f90d534338968c32c981cb2d2e
record_format dspace
spelling oai:doaj.org-article:f4d4a9f90d534338968c32c981cb2d2e2021-12-02T15:14:11ZManagement and Outcomes of Unilateral Group D Tumors in Retinoblastoma1177-5483https://doaj.org/article/f4d4a9f90d534338968c32c981cb2d2e2021-01-01T00:00:00Zhttps://www.dovepress.com/management-and-outcomes-of-unilateral-group-d-tumors-in-retinoblastoma-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Saima Amin,1 Mays AlJboor,1 Mario D Toro,2,3 Robert Rejdak,2 Katarzyna Nowomiejska,2 Rashed Nazzal,4 Mona Mohammad,1 Maysa Al-Hussaini,5 Jakub Khzouz,5 Sara Banat,1 Reem AlJabari,1 Imad Jaradat,6 Mustafa Mehyar,1 Iyad Sultan,7 Ibrahim AlNawaiseh,1 Yacoub A Yousef1 1Department of Surgery (Ophthalmology), King Hussein Cancer Centre (KHCC), Amman, Jordan; 2Department of General Ophthalmology and Pediatric Ophthalmology Service, Medical University of Lublin, Lublin, Poland; 3Faculty of Medical Sciences, Collegium Medicum Cardinal Stefan Wyszyński University, Warsaw, Poland; 4Shami Eye Center, Amman, Jordan; 5Department of Pathology, King Hussein Cancer Centre (KHCC), Amman, Jordan; 6Department of Radiation Oncology, King Hussein Cancer Centre (KHCC), Amman, Jordan; 7Department of Pediatric Oncology, King Hussein Cancer Centre (KHCC), Amman, JordanCorrespondence: Yacoub A YousefDepartment of Surgery (Ophthalmology), King Hussein Cancer Centre (KHCC), Queen Rania Al-Abdullah Street P.O Box 1269, Amman 11941, JordanTel +962 787228749Fax +962 5300460/1552Email yyousef@khcc.joMario D ToroDepartment of General Ophthalmology and Pediatric Ophthalmology Service, Medical University of Lublin, Ul. Chmielna 1, Lublin 20079, PolandTel +48 815326149Fax +48 815324827Email toro.mario@email.itPurpose: Retinoblastoma presents most commonly as advanced unilateral disease, particularly in developing countries for which primary enucleation has been the preferred method of treatment. However, with the evolution of newer treatment modalities including intravitreal chemotherapy, intra-arterial chemotherapy and newer chemotherapeutic combinations, a trend towards more conservative approaches is being observed. Our aim is to evaluate outcomes of group D eyes following conservative and non-conservative treatment options.Patients and Methods: The ocular oncology database was used to identify eyes with unilateral retinoblastoma that fulfilled the International Intraocular Retinoblastoma Classification (IIRC) group D criteria from August 2010 to August 2018 and these were retrospectively reviewed. Overall, 39 eyes were identified.Results: Nineteen (49%) eyes underwent primary enucleation and 20 (51%) received eye-conserving treatment. Eye salvage was possible in 15 (75%) eyes in the attempted salvage group. None of the patient revealed signs of metastasis. All eyes received conventional chemotherapy (carboplatin, vincristine, etoposide) and focal laser therapy. Additional treatment modalities offered included intravitreal chemotherapy, intra-arterial chemotherapy and topotecan. Three (11%) eyes in the primary enucleation group showed high-risk features on histopathology and none developed metastasis.Conclusion: The results of the study seem promising and conservative measures can be adopted in selected unilateral group D eyes.Keywords: ocular oncology, chemotherapy, enucleation, eye-conserving treatmentAmin SAlJboor MToro MDRejdak RNowomiejska KNazzal RMohammad MAl-Hussaini MKhzouz JBanat SAlJabari RJaradat IMehyar MSultan IAlNawaiseh IYousef YADove Medical Pressarticleocular oncologychemotherapyenucleationeye-conserving treatmentOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 15, Pp 65-72 (2021)
institution DOAJ
collection DOAJ
language EN
topic ocular oncology
chemotherapy
enucleation
eye-conserving treatment
Ophthalmology
RE1-994
spellingShingle ocular oncology
chemotherapy
enucleation
eye-conserving treatment
Ophthalmology
RE1-994
Amin S
AlJboor M
Toro MD
Rejdak R
Nowomiejska K
Nazzal R
Mohammad M
Al-Hussaini M
Khzouz J
Banat S
AlJabari R
Jaradat I
Mehyar M
Sultan I
AlNawaiseh I
Yousef YA
Management and Outcomes of Unilateral Group D Tumors in Retinoblastoma
description Saima Amin,1 Mays AlJboor,1 Mario D Toro,2,3 Robert Rejdak,2 Katarzyna Nowomiejska,2 Rashed Nazzal,4 Mona Mohammad,1 Maysa Al-Hussaini,5 Jakub Khzouz,5 Sara Banat,1 Reem AlJabari,1 Imad Jaradat,6 Mustafa Mehyar,1 Iyad Sultan,7 Ibrahim AlNawaiseh,1 Yacoub A Yousef1 1Department of Surgery (Ophthalmology), King Hussein Cancer Centre (KHCC), Amman, Jordan; 2Department of General Ophthalmology and Pediatric Ophthalmology Service, Medical University of Lublin, Lublin, Poland; 3Faculty of Medical Sciences, Collegium Medicum Cardinal Stefan Wyszyński University, Warsaw, Poland; 4Shami Eye Center, Amman, Jordan; 5Department of Pathology, King Hussein Cancer Centre (KHCC), Amman, Jordan; 6Department of Radiation Oncology, King Hussein Cancer Centre (KHCC), Amman, Jordan; 7Department of Pediatric Oncology, King Hussein Cancer Centre (KHCC), Amman, JordanCorrespondence: Yacoub A YousefDepartment of Surgery (Ophthalmology), King Hussein Cancer Centre (KHCC), Queen Rania Al-Abdullah Street P.O Box 1269, Amman 11941, JordanTel +962 787228749Fax +962 5300460/1552Email yyousef@khcc.joMario D ToroDepartment of General Ophthalmology and Pediatric Ophthalmology Service, Medical University of Lublin, Ul. Chmielna 1, Lublin 20079, PolandTel +48 815326149Fax +48 815324827Email toro.mario@email.itPurpose: Retinoblastoma presents most commonly as advanced unilateral disease, particularly in developing countries for which primary enucleation has been the preferred method of treatment. However, with the evolution of newer treatment modalities including intravitreal chemotherapy, intra-arterial chemotherapy and newer chemotherapeutic combinations, a trend towards more conservative approaches is being observed. Our aim is to evaluate outcomes of group D eyes following conservative and non-conservative treatment options.Patients and Methods: The ocular oncology database was used to identify eyes with unilateral retinoblastoma that fulfilled the International Intraocular Retinoblastoma Classification (IIRC) group D criteria from August 2010 to August 2018 and these were retrospectively reviewed. Overall, 39 eyes were identified.Results: Nineteen (49%) eyes underwent primary enucleation and 20 (51%) received eye-conserving treatment. Eye salvage was possible in 15 (75%) eyes in the attempted salvage group. None of the patient revealed signs of metastasis. All eyes received conventional chemotherapy (carboplatin, vincristine, etoposide) and focal laser therapy. Additional treatment modalities offered included intravitreal chemotherapy, intra-arterial chemotherapy and topotecan. Three (11%) eyes in the primary enucleation group showed high-risk features on histopathology and none developed metastasis.Conclusion: The results of the study seem promising and conservative measures can be adopted in selected unilateral group D eyes.Keywords: ocular oncology, chemotherapy, enucleation, eye-conserving treatment
format article
author Amin S
AlJboor M
Toro MD
Rejdak R
Nowomiejska K
Nazzal R
Mohammad M
Al-Hussaini M
Khzouz J
Banat S
AlJabari R
Jaradat I
Mehyar M
Sultan I
AlNawaiseh I
Yousef YA
author_facet Amin S
AlJboor M
Toro MD
Rejdak R
Nowomiejska K
Nazzal R
Mohammad M
Al-Hussaini M
Khzouz J
Banat S
AlJabari R
Jaradat I
Mehyar M
Sultan I
AlNawaiseh I
Yousef YA
author_sort Amin S
title Management and Outcomes of Unilateral Group D Tumors in Retinoblastoma
title_short Management and Outcomes of Unilateral Group D Tumors in Retinoblastoma
title_full Management and Outcomes of Unilateral Group D Tumors in Retinoblastoma
title_fullStr Management and Outcomes of Unilateral Group D Tumors in Retinoblastoma
title_full_unstemmed Management and Outcomes of Unilateral Group D Tumors in Retinoblastoma
title_sort management and outcomes of unilateral group d tumors in retinoblastoma
publisher Dove Medical Press
publishDate 2021
url https://doaj.org/article/f4d4a9f90d534338968c32c981cb2d2e
work_keys_str_mv AT amins managementandoutcomesofunilateralgroupdtumorsinretinoblastoma
AT aljboorm managementandoutcomesofunilateralgroupdtumorsinretinoblastoma
AT toromd managementandoutcomesofunilateralgroupdtumorsinretinoblastoma
AT rejdakr managementandoutcomesofunilateralgroupdtumorsinretinoblastoma
AT nowomiejskak managementandoutcomesofunilateralgroupdtumorsinretinoblastoma
AT nazzalr managementandoutcomesofunilateralgroupdtumorsinretinoblastoma
AT mohammadm managementandoutcomesofunilateralgroupdtumorsinretinoblastoma
AT alhussainim managementandoutcomesofunilateralgroupdtumorsinretinoblastoma
AT khzouzj managementandoutcomesofunilateralgroupdtumorsinretinoblastoma
AT banats managementandoutcomesofunilateralgroupdtumorsinretinoblastoma
AT aljabarir managementandoutcomesofunilateralgroupdtumorsinretinoblastoma
AT jaradati managementandoutcomesofunilateralgroupdtumorsinretinoblastoma
AT mehyarm managementandoutcomesofunilateralgroupdtumorsinretinoblastoma
AT sultani managementandoutcomesofunilateralgroupdtumorsinretinoblastoma
AT alnawaisehi managementandoutcomesofunilateralgroupdtumorsinretinoblastoma
AT yousefya managementandoutcomesofunilateralgroupdtumorsinretinoblastoma
_version_ 1718387606727688192